Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a large growth in short interest in April. As of April 15th, there was short interest totaling 463,930 shares, a growth of 885.4% from the March 31st total of 47,081 shares. Currently, 30.9% of the shares of the stock are sold short. Based on an average daily volume of 2,402,691 shares, the days-to-cover ratio is currently 0.2 days.

Clearmind Medicine Trading Down 0.8%

Shares of Clearmind Medicine stock traded down $0.01 during mid-day trading on Friday, reaching $0.81. 1,819,695 shares of the stock were exchanged, compared to its average volume of 3,828,751. The company has a market cap of $1.22 million, a price-to-earnings ratio of -0.04 and a beta of 1.32. The firm has a 50-day simple moving average of $1.00 and a 200 day simple moving average of $8.89. Clearmind Medicine has a fifty-two week low of $0.59 and a fifty-two week high of $52.40.

Clearmind Medicine (NASDAQ:CMND) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($3.32) earnings per share for the quarter.

Institutional Investors Weigh In On Clearmind Medicine

An institutional investor recently raised its position in Clearmind Medicine stock. AdvisorShares Investments LLC lifted its holdings in shares of Clearmind Medicine Inc. (NASDAQ:CMND) by 9.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 224,378 shares of the company’s stock after buying an additional 18,445 shares during the quarter. AdvisorShares Investments LLC owned about 4.10% of Clearmind Medicine worth $230,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 96.05% of the company’s stock.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.